NeuroDerm
Drug-device Combination Solutions for Central Nervous System Disorders
StartupNeuroDerm is a Rehovot-based startup in the Health Tech & Life Sciences sector, established in 2003. Drug-device Combination Solutions for Central Nervous System Disorders. The company has raised a total of $63.5M across 3 funding rounds, currently at the Acquired stage. Key investors include The Elias Group, Robert Taub. The company has 51-200 employees. Core technologies: Biologicals.
With $63.5M in total funding, NeuroDerm is a Acquired-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent. NeuroDerm has been acquired.
- StageAcquired
- ProductClinical Trial
- ModelB2B
- Employees51-200
- HQRehovot
- DistrictCenter District
- StatusAcquired
- Last Round$45M
- The Elias Group
- Robert Taub
10 articles covered by sources including www.prnewswire.com,
globenewswire.com,
www.globes.co.il,
www.reuters.com.
What does NeuroDerm do?
NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim of reducing disease burden and improving the quality of life of patients and their families. NeuroDerm’s flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. Its system for self-administered continuous subcutaneous infusion of the gold standard levodopa/carbidopa, was designed specifically to be a user-friendly system for people with Parkinson's disease, to maintain steady therapeutic levodopa plasma concentrations for the purpose of improving fluctuations, that is, reducing patients’ "OFF" time without increasing troublesome dyskinesia. Its tailored solution potentially offers sustained relief (compared to oral immediate-release levodopa/carbidopa treatments) and empowers patients and their families to regain control of their lives with greater daily-life predictability and independence.
How much funding has NeuroDerm raised?
NeuroDerm has raised $63.5M in total funding across 3 rounds. The company is currently at the Acquired stage. Key investors include The Elias Group, Robert Taub.
What sector is NeuroDerm in?
NeuroDerm operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is NeuroDerm located?
NeuroDerm is based in Prof. Haim Pekeris 3, Rehovot, Israel, Center District.